Disappearance rate of insulin antibodies after discontinuing insulin treatment in 42 type 2 (non-insulin-dependent) diabetic patients. 1984

C Ionescu-Tîrgovişte, and I Mincu, and L Simionescu, and D Cheţa, and Z Mirodon, and E Sântu, and E Popa, and A Bîrnea

The disappearance rate of insulin antibodies was studied after cessation of insulin treatment which had been given for 3 months to 6 years in 42 Type 2 (non-insulin-dependent) diabetic patients. Insulin antibodies were measured before and 15 days after interruption of insulin treatment, and every 30 days until the disappearance of insulin antibodies. The mean +/- SD value of insulin binding in the entire group before the interruption of insulin treatment was 32 +/- 14%. There was no relationship between the antibody level at that time and the duration of insulin treatment. However, the insulin antibody level was significantly higher in 17 diabetic patients on an insulin dose of greater than 20 U/day (p less than 0.02) than in 25 on an insulin dose of less than 20 U/day (39 +/- 13% versus 28 +/- 12%). A positive correlation was found between initial insulin binding and the time required for it to fall below 10% (r = 0.74). Antibodies were absent 60 days after discontinuing insulin treatment in eight of ten subjects presenting with initial binding of less than 20%. In contrast, in only two of 12 patients with an initial binding of greater than 40% were insulin antibodies detectable 150 days after discontinuation of insulin therapy. Disappearance of insulin antibodies sometimes took up to 1 year and occasionally even more than 2 years.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007330 Insulin Antibodies Antibodies specific to INSULIN. Antibodies, Insulin
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

C Ionescu-Tîrgovişte, and I Mincu, and L Simionescu, and D Cheţa, and Z Mirodon, and E Sântu, and E Popa, and A Bîrnea
September 1982, Diabetologia,
C Ionescu-Tîrgovişte, and I Mincu, and L Simionescu, and D Cheţa, and Z Mirodon, and E Sântu, and E Popa, and A Bîrnea
September 1991, Diabetologia,
C Ionescu-Tîrgovişte, and I Mincu, and L Simionescu, and D Cheţa, and Z Mirodon, and E Sântu, and E Popa, and A Bîrnea
October 1994, Diabetes research and clinical practice,
C Ionescu-Tîrgovişte, and I Mincu, and L Simionescu, and D Cheţa, and Z Mirodon, and E Sântu, and E Popa, and A Bîrnea
December 1992, Diabetologia,
C Ionescu-Tîrgovişte, and I Mincu, and L Simionescu, and D Cheţa, and Z Mirodon, and E Sântu, and E Popa, and A Bîrnea
October 1993, Diabetologia,
C Ionescu-Tîrgovişte, and I Mincu, and L Simionescu, and D Cheţa, and Z Mirodon, and E Sântu, and E Popa, and A Bîrnea
September 1992, Diabetologia,
C Ionescu-Tîrgovişte, and I Mincu, and L Simionescu, and D Cheţa, and Z Mirodon, and E Sântu, and E Popa, and A Bîrnea
October 1988, Diabetes research (Edinburgh, Scotland),
C Ionescu-Tîrgovişte, and I Mincu, and L Simionescu, and D Cheţa, and Z Mirodon, and E Sântu, and E Popa, and A Bîrnea
February 1988, Diabetologia,
C Ionescu-Tîrgovişte, and I Mincu, and L Simionescu, and D Cheţa, and Z Mirodon, and E Sântu, and E Popa, and A Bîrnea
January 1985, Annals of clinical research,
C Ionescu-Tîrgovişte, and I Mincu, and L Simionescu, and D Cheţa, and Z Mirodon, and E Sântu, and E Popa, and A Bîrnea
January 1989, European journal of nuclear medicine,
Copied contents to your clipboard!